SCHEMBL1103591

SCHEMBL1103591

c1ccc2cc(-c3c4ccccc4c(-c4cccc5ccccc45)c4c3cnc3ccccc34)ncc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ GPR3 P46089 1/20 0.41
▸ PDPK1 O15530 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RAB9A P51151 1/20 0.34
▸ GSK3B P49841 1/20 0.34
▸ CDK5 Q00535 1/20 0.34
▸ CDK5R1 Q15078 1/20 0.34
▸ CYP1A2 P05177 2/20 0.33
▸ CDK4 P11802 2/20 0.33
▸ CCND1 P24385 2/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ TDO2 P48775 1/20 0.33
▸ GRM4 Q14833 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ SENP8 Q96LD8 1/20 0.33
▸ SENP7 Q9BQF6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103247 0.86 KDM4E (0.46) NPC1KDM4EGPR3PDPK1MEN1
SCHEMBL1103468 0.85 KDM4E (0.44) NPC1KDM4EGPR3PDPK1MEN1
SCHEMBL24662854 0.85 NPC1 (0.51) NPC1KDM4EPDPK1MEN1KMT2A
SCHEMBL1103587 0.84 KDM4E (0.46) NPC1KDM4EGPR3MEN1KMT2A
SCHEMBL1103409 0.84 ESR1 (0.43) NPC1KDM4EGPR3PDPK1RAB9A
SCHEMBL1103557 0.84 KDM4E (0.41) NPC1KDM4EGPR3PDPK1MEN1
SCHEMBL1103453 0.83 MET (0.42) NPC1KDM4EGPR3PDPK1MEN1
SCHEMBL1103569 0.82 KDM4E (0.42) NPC1KDM4EGPR3PDPK1MEN1
SCHEMBL1103533 0.82 KDM4E (0.41) NPC1KDM4EGPR3PDPK1RAB9A
SCHEMBL1103562 0.82 KDM4E (0.42) NPC1KDM4EGPR3PDPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 NPC1 1582/4885KDM4E 3367/4885GPR3 1503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback